Vildagliptin is an oral antidiabetic medicine used in the management of type 2 diabetes mellitus (T2DM). It belongs to the class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Vildagliptin works by enhancing the body's natural incretin hormones, which help regulate blood glucose levels in a glucose-dependent manner.

By improving insulin release after meals and reducing excess glucagon secretion, Vildagliptin supports better glycaemic control without causing significant hypoglycaemia. It is commonly prescribed alone or in combination with other antidiabetic medicines such as metformin, sulfonylureas, or insulin.

Vildagliptin is a well-established DPP-4 inhibitor explicitly developed for improving post-meal and fasting blood glucose control in adults with type 2 diabetes. Unlike some older antidiabetic medicines that act independently of glucose levels, Vildagliptin works in harmony with the body's physiological glucose regulation system.

After food intake, incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are released from the gut. These hormones stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. However, they are rapidly broken down by the DPP-4 enzyme. Vildagliptin inhibits this enzyme, thereby prolonging incretin activity and improving glycaemic control.

The 50 mg strength is one of the most commonly prescribed doses and is used either once or twice daily, depending on the treatment regimen. Vildagliptin is especially useful in patients who require effective glucose control with a low risk of hypoglycaemia and minimal impact on body weight.

Vildagliptin is widely used in the treatment of type 2 diabetes mellitus (T2DM) to help achieve better and more consistent blood sugar control. It is particularly valued for its glucose-dependent action and good tolerability, making it suitable for a broad range of adult patients.

Vildagliptin is prescribed for adults with T2DM when lifestyle measures such as diet modification and regular physical activity do not adequately control blood glucose levels. Improving the body's natural incretin response helps lower both fasting and post-meal blood sugar levels without causing excessive insulin release.

Monotherapy in Metformin-Intolerant Patients

In patients who cannot tolerate metformin due to gastrointestinal side effects or who have contraindications such as renal impairment, Vildagliptin may be used alone. Its mechanism allows effective glucose control without the gastrointestinal discomfort commonly seen with other oral antidiabetic drugs.

Combination Therapy

Vildagliptin is commonly used in combination with other antidiabetic agents when single-drug therapy does not achieve target HbA1c levels. It can be safely combined with metformin, sulfonylureas, thiazolidinediones, or insulin. In combination regimens, Vildagliptin complements other mechanisms of action, leading to improved overall glycaemic control while maintaining a low risk of hypoglycaemia.

Control of Post-Prandial Hyperglycaemia

One of the key benefits of Vildagliptin is its ability to reduce post-meal blood sugar spikes. By enhancing incretin hormone activity, it increases insulin secretion and suppresses glucagon release in a glucose-dependent manner, helping to smooth post-prandial glucose fluctuations.

Use in Elderly Patients with Diabetes

Vildagliptin is often considered a suitable option for elderly individuals with type 2 diabetes. Its low risk of hypoglycaemia, neutral effect on body weight, and overall safety profile make it a practical choice in older patients, especially those with multiple comorbidities or a higher risk of adverse effects from other antidiabetic therapies.

Reliable Glycaemic Control

Vildagliptin helps lower both fasting and post-prandial blood glucose levels by improving the body's natural incretin response. With regular use, it contributes to meaningful reductions in HbA1c, supporting sustained long-term blood sugar control in people with type 2 diabetes.

Low Risk of Hypoglycaemia

Its glucose-dependent mechanism ensures that insulin release is enhanced only when blood sugar levels are elevated. This significantly reduces the likelihood of hypoglycaemic episodes, especially when compared with sulfonylureas or insulin-based regimens.

Weight-Neutral Profile

Unlike many traditional antidiabetic medicines, Vildagliptin typically does not cause weight gain. This makes it a suitable option for patients who are overweight or concerned about weight changes during diabetes treatment.

Good Tolerability and Safety

Vildagliptin is generally well tolerated, with a low incidence of gastrointestinal side effects such as nausea or diarrhoea. Its favourable safety profile makes it suitable for long-term use, including in elderly patients when appropriately monitored.

Flexible Treatment Option

The medicine can be prescribed as monotherapy or in combination with other antidiabetic agents, such as metformin, insulin, or thiazolidinediones. This flexibility allows clinicians to individualise therapy based on disease severity, patient tolerance, and treatment goals.

Vildagliptin is generally well tolerated. Most side effects are mild and transient.

Common Side Effects:

1. Headache

2. Dizziness

3. Nasopharyngitis (cold-like symptoms)

4. Mild gastrointestinal discomfort

Less Common Side Effects:

1. Fatigue

2. Joint pain

3. Mild skin reactions

Rare but Serious Side Effects (Seek medical attention):

1. Signs of pancreatitis (persistent severe abdominal pain)

2. Severe allergic reactions, such as swelling or rash

3. Liver enzyme abnormalities

The usual dose is 50 mg once or twice daily, as prescribed by the doctor.

1. Administration:

2. Swallow the tablet whole with water. It can be taken with or without food.

3. Consistency:

4. Take the medicine at the same time each day for the best results.

5. Monitoring:

6. Regular monitoring of blood glucose and HbA1c is recommended.

7. Do Not Stop Abruptly:

8. Discontinuation should only be done under medical advice.

Vildagliptin controls blood glucose by blocking the dipeptidyl peptidase-4 (DPP-4) enzyme, which usually breaks down incretin hormones. Preserving these hormones strengthens the body's natural response to rising blood sugar levels.

Key Actions:

1. Prolongs the activity of incretins such as GLP-1 and GIP

2. Promotes insulin release only when blood glucose is elevated

3. Reduces excess glucagon secretion after meals

4. Limits glucose production by the liver

Metabolic Benefits:

1. Better control of post-meal glucose spikes

2. More consistent blood sugar levels throughout the day

3. Sustained improvement in long-term glycaemic control

As its effects are glucose-dependent, Vildagliptin carries a very low risk of hypoglycaemia when used alone.

1. Store below 30°C.

2. Protect from moisture and direct sunlight.

3. Keep out of reach of children.

1. Food: Can be taken with or without meals. Food does not significantly affect absorption.

2. Alcohol: Excessive alcohol intake should be avoided as it may worsen glycaemic control.

1. Insulin or Sulfonylureas: May increase the risk of hypoglycaemia; dose adjustment may be needed.
2. Other Antidiabetic Medicines: Generally safe when used as part of combination therapy.

1. Liver Disease:

2. Use with caution; liver function tests should be monitored.

3. Renal Impairment:

4. Dose adjustment may be required in moderate to severe kidney disease.

5. History of Pancreatitis:

6. Use only under specialist supervision.

The usual adult dose is:

1. 50 mg once daily or

2. 50 mg twice daily, depending on the combination regimen and patient profile.

A healthcare professional should make all dosing decisions.

Possible Symptoms:

1. Dizziness

2. Headache

3. Mild gastrointestinal symptoms

Action Required:

Seek medical advice for observation and supportive care.

1. Take the missed dose as soon as you remember.

2. If it is almost time for the next dose, skip the missed one.

3. Do not take two doses together.